Terug
4
Ook genoteerd als
SHPMY
OTC
Dagbereik
€ 1,46
€ 1,46
52-Weeksbereik
€ 1,46
€ 15,70
Volume
100
50D / 200D Gem.
€ 1,49
/
€ 1,53
Vorige Slotkoers
€ 1,46
Quick Summary
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (631 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 1,9 | 0,2 |
| P/B | 0,1 | 3,0 |
| ROE % | 6,5 | 3,6 |
| Net Margin % | 1,7 | 3,8 |
| Rev Growth 5Y % | 9,4 | 9,9 |
| D/E | 0,7 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2027 |
€ 1,50
€ 1,43 – € 1,59
|
317,47B | 1 |
| FY2026 |
€ 1,36
€ 1,30 – € 1,45
|
300,70B | 1 |
No quarterly estimates available
Earnings Surprises
Last 8 quarters
| Quarter | Est. EPS | Actual EPS | Surprise |
|---|---|---|---|
| 2025-04-28 | € 0,06 | € 0,05 | -17,8% |
| 2024-12-31 | N/A | € 0,02 | — |
| 2024-10-29 | € 0,04 | € 0,04 | +9,7% |
| 2024-08-26 | € 0,05 | € 0,05 | +1,4% |
| 2024-04-26 | € 0,06 | € 0,06 | -1,0% |
| 2023-12-31 | N/A | € 0,00 | — |
| 2023-09-30 | € 0,06 | € 0,04 | -20,9% |
| 2023-06-30 | € 0,09 | € 0,04 | -53,9% |
Dividend History
7 yr streakYield
0,01%
Payout Ratio
0,79%
Growth (3Y)
-2,89%
Growth (5Y)
-34,64%
| Ex-Date | Payment Date | Amount | Yield |
|---|---|---|---|
| Dec 29, 2025 | Feb 06, 2026 | € 0,02 | 3,75% |
| Jul 16, 2025 | Aug 25, 2025 | € 0,04 | 3,31% |
| Sep 17, 2024 | Oct 25, 2024 | € 0,01 | 0,68% |
| Jul 18, 2024 | Aug 27, 2024 | € 0,06 | 0,37% |
| Jul 18, 2023 | Aug 28, 2023 | € 0,08 | 0,46% |
| Jul 20, 2022 | Aug 29, 2022 | € 0,06 | 0,40% |
| Jul 15, 2021 | Aug 27, 2021 | € 0,07 | 0,36% |
| Jul 17, 2020 | Aug 21, 2020 | € 0,48 | 2,79% |
| Jul 12, 2019 | Aug 23, 2019 | € 0,47 | 2,33% |
| Jul 12, 2018 | Aug 24, 2018 | € 0,06 | 0,21% |
| Jul 12, 2017 | Aug 21, 2017 | € 0,05 | 0,20% |
| Jul 15, 2016 | — | € 0,39 | 1,82% |
| Jun 17, 2015 | — | € 0,37 | 1,84% |
| May 22, 2014 | — | € 0,33 | 1,36% |
| Jun 19, 2013 | — | € 0,30 | 1,47% |
Belangrijkste Punten
Revenue grew 9,44% annually over 5 years — modest growth
Earnings grew 20,82% over the past year
Generating 3,43B in free cash flow
P/E of 1,86 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 3,69%
Capital efficient — spends only 0,87% of revenue on capex
Groei
Revenue Growth (5Y)
9,44%
Revenue (1Y)5,75%
Earnings (1Y)20,82%
FCF Growth (3Y)29,02%
Kwaliteit
Return on Equity
6,49%
ROIC5,11%
Net Margin1,65%
Op. Margin2,96%
Veiligheid
Debt / Equity
0,67
Current Ratio1,36
Interest Coverage5,01
Waardering
P/E Ratio
1,86
Forward P/E1,07
P/B Ratio0,12
EV/EBITDA2,52
Dividend Yield0,01%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 5,75% | Revenue Growth (3Y) | 8,93% |
| Earnings Growth (1Y) | 20,82% | Earnings Growth (3Y) | -9,97% |
| Revenue Growth (5Y) | 9,44% | Earnings Growth (5Y) | 0,31% |
| Profitability | |||
| Revenue (TTM) | 275,25B | Net Income (TTM) | 4,55B |
| ROE | 6,49% | ROA | 2,06% |
| Gross Margin | 11,13% | Operating Margin | 2,96% |
| Net Margin | 1,65% | Free Cash Flow (TTM) | 3,43B |
| ROIC | 5,11% | FCF Growth (3Y) | 29,02% |
| Safety | |||
| Debt / Equity | 0,67 | Current Ratio | 1,36 |
| Interest Coverage | 5,01 | ||
| Dividends | |||
| Dividend Yield | 0,01% | Payout Ratio | 0,79% |
| Dividend Growth (3Y) | -2,89% | Dividend Growth (5Y) | -34,64% |
| Consecutive Div Years | 7 yrs | ||
| Valuation | |||
| P/E Ratio | 1,86 | Forward P/E | 1,07 |
| P/B Ratio | 0,12 | P/S Ratio | 0,03 |
| PEG Ratio | 4,73 | Forward PEG | N/A |
| EV/EBITDA | 2,52 | Fwd EV/EBITDA | 1,40 |
| Forward P/S | 0,03 | Fwd Earnings Yield | 93,46% |
| FCF Yield | 40,50% | ||
| Market Cap | 8,46B | Enterprise Value | 20,51B |
Income Statement
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 275,25B | 260,30B | 231,98B | 215,82B | 191,91B |
| Net Income | 4,55B | 3,77B | 5,62B | 5,09B | 4,50B |
| EPS (Diluted) | 1,23 | 1,02 | 1,61 | 1,79 | 1,58 |
| Gross Profit | 30,63B | 31,33B | 30,49B | 28,54B | 27,44B |
| Operating Income | 8,14B | 7,67B | 9,01B | 8,21B | 7,18B |
Balance Sheet
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 221,21B | 211,97B | 198,13B | 163,44B | 149,19B |
| Total Liabilities | 137,47B | 131,65B | 120,13B | 104,37B | 94,44B |
| Shareholders' Equity | 71,68B | 68,52B | 67,06B | 49,36B | 45,35B |
| Total Debt | 47,79B | 42,90B | 38,56B | 31,69B | 31,79B |
| Cash & Equivalents | 35,74B | 30,52B | 27,40B | 22,39B | 22,30B |
| Current Assets | 171,82B | 162,43B | 149,51B | 116,49B | 107,56B |
| Current Liabilities | 126,04B | 122,37B | 110,69B | 91,82B | 88,13B |
Strategiescores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
#608 of 619
Recente Activiteit
Ingestapt
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026